Table 1 Clinical characteristics and assessments at baseline, post-treatment, and at 3- and 6-month follow-up (n = 25)
Age (years) | Gender | Comorbidities (K-SADS) | Medication (dose/day) | Number of sessions: face-to-face/webcam | CY-BOCS total score | CGI–Severity / CGI-Improvement | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pre | Post | 3 m | 6 m | Pre | Post | 3 m | 6 m | |||||
12 | M | SAD, GAD, ADHD, Tic disorder, ASD | Guanfacine (4 mg) | 14/1 | 34 | 17 | 0 | 0 | 6 | 3/2 | 1/1 | 1/1 |
17 | F | None | None | 9/6 | 25 | 6 | 0 | 0 | 5 | 1/1 | 1/1 | 1/1 |
9 | M | Depression, Eating disorder | None | 7/1 | 18 | 11 | 11 | 21 | 4 | 1/2 | 1/3 | 5/3 |
16 | F | None | None | 10/11 | 18 | 14 | 18 | N.A | 4 | 4/3 | 5/3 | N.A |
10 | F | SAD, Spec. phobia, ADHD, Tic disorder | None | 6/1 | 25 | 0 | 0 | 0 | 5 | 1/1 | 1/1 | 1/1 |
10 | F | GAD | None | 6/3 | 24 | 0 | 0 | 0 | 4 | 1/1 | 1/1 | 1/1 |
17 | M | Tic disorder | None | 10/2 | 35 | 22 | 20 | 18 | 6 | 4/3 | 2/4 | 1/4 |
15 | F | None | None | 10/2 | 24 | 2 | 2 | 2 | 5 | 1/1 | 1/1 | 1/1 |
13 | M | Tic disorder | None | 10/6 | 31 | 8 | 0 | 0 | 5 | 4/1 | 1/1 | 1/1 |
12 | F | Eating disorder | Risperidone (1 mg) | 14/1 | 34 | 33 | N.A | 5 | 6 | 6/3 | N.A | 1/1 |
13 | F | GAD | None | 10/7 | 31 | 23 | N.A | N.A | 6 | 5/3 | N.A | N.A |
13 | F | None | Methylphenidate (40 mg) | 9/4 | 20 | 5 | 2 | 1 | 4 | 1/1 | 1/1 | 1/6 |
14 | F | None | None | 12/9 | 27 | 7 | 4 | 19 | 5 | 1/1 | 2/1 | 4/3 |
17 | M | ASD | None | 3/2 | 21 | 0 | N.A | N.A | 5 | 1/1 | N.A | N.A |
8 | F | None | None | 7/5 | 25 | 0 | 0 | 0 | 4 | 1/1 | 1/1 | 1/1 |
13 | M | None | None | 10/6 | 30 | 0 | 0 | 0 | 4 | 1/1 | 1/1 | 1/1 |
16 | M | N.A | None | 7/7 | 25 | 20 | N.A | N.A | 5 | 4/3 | N.A | N.A |
13 | F | ASD | None | 10/3 | 29 | 12 | 1 | 0 | 6 | 3/1 | 1/2 | 1/1 |
13 | F | None | None | 9/4 | 18 | 12 | 12 | 12 | 4 | 3/3 | 3/3 | 2/3 |
8 | M | None | None | 8/3 | 31 | 0 | 0 | 0 | 5 | 1/1 | 1/1 | 1/1 |
14 | M | Bipolar disorder | Aripiprazole (20 mg) | 4/6 | 21 | 17 | N.A | N.A | 4 | 3/3 | N.A | N.A |
17 | F | None | None | 8/9 | 32 | 0 | 0 | 0 | 5 | 1/1 | 1/1 | 1/1 |
8 | M | PTSD | None | 7/5 | 20 | 10 | 2 | 0 | 4 | 1/2 | 1/1 | 1/1 |
16 | F | Spec. phobia, ADHD | Methylphenidate (20 mg) | 11/4 | 21 | 14 | 6 | 3 | 5 | 2/1 | 2/1 | 1/1 |
14 | M | ASD, Tic disorder | None | 9/4 | 25 | 0 | 0 | 0 | 3 | 1/1 | 1/1 | 1/1 |